Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats

European Journal of Pharmacology

Volumn 368, Issue 2-3, 1999, Pages 149-159

  De Sarro, Giovambattista ^a   Di Paola, Eugenio Donato ^a   Gareri, Pietro ^a   Gallelli, Luca ^a   Scotto, Gisella ^a   De Sarro, Angela ^a  

^a NONE

Author keywords

2,3 Benzodiazepine, AMPA receptor antagonist; Anticonvulsants; Audiogenic seizure; Epilepsy; Genetically epilepsy prone rat; Kindling; Pentylenetetrazole; Tolerance

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG TOLERANCE; EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; BENZODIAZEPINONES; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; KINDLING, NEUROLOGIC; MALE; MOTOR ACTIVITY; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0033051140     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00006-0     Document Type: Article

References (61)

1. Bawin S.M., Satmary W.M., Sheppard A.R., Adey W.R. Roles of the NMDA and quisqualate/kainate receptors in the induction and expression of kindled bursts in rat hippocampal slices. Epilepsy Res. 15:1993;7-13.
2. Belleville R.E., Fraser H.F. Tolerance to some effects of barbiturates. J. Pharmacol. Exp. Ther. 120:1957;469-474.
3. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
4. Block F., Schwarz M. The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors. Eur. J. Pharmacol. 256:1994;149-153.
5. Boast C.A., Pastor G., Gerhardt S.C., Hall N.R., Liebman J.M. Behavioral tolerance and sensitization to CGS 19755, a competitive N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. 147:1988;556-561.
6. Bradford H.F. Glutamate, GABA and epilepsy. Prog. Neurobiol. 47:1995;477-511.
7. Cain D.P., Desorough K.A., Mckitric D.J. Retardation of amygdala kindling by antagonism of NMD-aspartate and muscarinic cholinergic receptors: evidence for the summation of excitatory mechanisms in kindling. Exp. Neurol. 100:1988;179-187.
8. Chapman, A.G., 1988. Anticonvulsant activity of excitatory amino acid antagonists. In: Cavalheeiro, E.A., Lehmann, J., Turski, L. (Eds.), Frontiers in Excitatory Amino Acid Research. Alan Liss, New York, pp. 203-210.
9. Chapman A.G., Smith S.E., Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466 in DBA/2 mice. Epilepsy Res. 9:1991;92-96.
10. Chimirri A., De Sarro G.B., De Sarro A., Gitto R., Grasso S., Quartarone S., Zappalà M., Giusti P., Libri V., Costanti A., Chapman A.G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem. 40:1997;1258-1269.
11. Collingridge G.L., Bliss T.V.P. NMDA receptor: their role in long-term potentiation. TINS. 10:1987;288-294.
12. Croucher M.J., Bradford H.F., Sunter D.C., Watkins J.C. Inhibition of the development of electrical kindling of the prepyriform cortex by daily focal injections of excitatory amino acid antagonists. Eur. J. Pharmacol. 152:1988;29-38.
13. De Sarro G.B., De Sarro A. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology. 32:1993;51-58.
14. De Sarro G.B., Patel S., Meldrum B.S. Anticonvulsant action of a kainate antagonist γ-glutamylaminomethylsulphonic acid (GAMS) injected focally into the substantia nigra and entopeduncular nucleus. Eur. J. Pharmacol. 132:1987;229-236.
15. De Sarro G.B., De Sarro A., Federico F., Meldrum B.S. Anticonvulsant properties of some calcium antagonists on sound-induced seizures in genetically epilepsy-prone rats. Gen. Pharmacol. 21:1990;769-778.
16. De Sarro, G.B., Rotiroti, D., Gratteri, S., Sinopoli, S., Iuliano, M., De Sarro, A., 1992. Tolerance to anticonvulsant effects of clobazam, diazepam and clonazepam in genetically epilepsy-prone rats. In: Biggio, G., Concas, A., Costa, E. (Eds.), GABAergic synaptic transmission. Adv. in Biochemical Pharmacology, Vol. 47. Raven Press, New York, pp. 249-254.
17. De Sarro G.B., Chimirri A., De Sarro A., Gitto R., Grasso S., Giusti P., Chapman A.G. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J. Pharmacol. 294:1995;411-422.
18. De Sarro G.B., Donato Di Paola E., Aguglia U., De Sarro A. Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy-prone rats. Pharmacol. Biochem. Behav. 55:1996;39-48.
19. De Sarro G.B., De Sarro A., Ammendola D., Patel S. Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP 37849 and CGP 39551 in genetically epilepsy-prone rats. Brain Res. 734:1996;91-97.
20. De Sarro G.B., Rizzo M., Sinopoli V.A., Gitto R., De Sarro A., Zappalà M., Chimirri A. Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats. Pharmacol. Biochem. Behav. 60:1999;123. in press.
21. Domino, E.F., Luby, E.D., 1981. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino, E.F. (Ed.), PCP (Phencyclidine): Historical and Current Perspectives. NPP Books: Ann Arbor, pp. 401-418.
22. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Ass. 46:1957;208-209.
23. Dürmüller N., Craggs M., Meldrum B.S. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174.
24. File S.E. Tolerance to the anti-pentylenetetrazole effects of diazepam in the mouse. Psychopharmacology. 79:1983;284-286.
25. Gastaut H., Low M.D. Antiepileptic properties of clobazam, a 1,5 benzodiazepine in man. Epilepsia. 20:1979;437-446.
26. Holmes K.H., Bilkey D.K., Laverty R., Goddard G.V. The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures. Brain Res. 506:1990;227-235.
27. Honoré T., Davies S.N., Drejer J., Fletcher E.J., Jacobsen P., Lodge D., Nielsen F.E. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 241:1988;701-703.
28. Jobe, P.C., 1981. Pharmacology of audiogenic seizures. In: Brown, R.D., Daigneault, E.A. (Eds.) Pharmacology of Hearing. Experiment and Clinical Bases. Wiley, New York, pp. 271-304.
29. Katayama K., Morimoto K., Sato K., Ohnishi M., Okamoto M., Otsuki S. The role of NMDA receptors in epilepsy. 1: Effects of NMDA receptor antagonists (CPP and MK-801) on amygdala kindling in rats. Jpn. J. Psychiatry Neurol. 44:1990;451-452.
30. Kraus J.E., Yeh G.C., Bonhaus D.W., Nadler J.V., McNamara J.O. Kindling induces the long-lasting expression of a novel population of NMDA receptors in hippocampal region CA3. J. Neurosci. 14:1994;4196-4205.
31. Lippa A.S., Regan B. Additional studies on the importance of glycine and GABA in mediating the actions of benzodiazepines. Life Sci. 21:1977;1779-1784.
32. Litchfield J.T., Wilcoxon F. A simplifield method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
33. Lodge, D., Aram, J.A., Church, J., Davies, S.N., Martin, D., Millar, J., Zeman, S., 1988. Sigma opiates and excitatory amino acids. In: Lodge, D. (Ed.). Excitatory Amino Acids in Health and Disease. Wiley, Chichester, pp. 237-259.
34. Löscher W. Which animal models should be used in the search for new antiepileptic drugs. Epilepsia. 34:1993;188.
35. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54:1998;721-741.
36. Löscher W., Hönack D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 259:1994;R3-R5.
37. Löscher W., Hönack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113:1994;1349-1357.
38. Löscher W., Nolting B., Hönack D. Evaluation of CPP, a selective NMDA antagonists, in various rodent models of epilepsy. Comparison with other NMDA antagonists,and with diazepam and phenobarbital. Eur. J. Pharmacol. 152:1988;9-17.
39. Löscher W., Rundfeldt C., Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 5:1993;1545-1550.
40. Majkowski, J., 1989. Kindling and memory. In: Trimble, M.R., Boldwig, T.G. (Eds.), The Clinical Relevance of Kindling. Wiley, Chichester, pp. 211-230.
41. McNamara J.O. Development of new pharmacological agents for epilepsy; lessons from the kindling model. Epilepsia. 30:1989;S13-S18.
42. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 14:1994;3413-3425.
43. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by and N-methyl-D-aspartate receptor antagonist. Nature. 319:1986;774-776.
44. Moshé, S., Ludwig, N., 1988. Kindling. In: Pedley T., Meldrum B.S. (Eds.), Recent Advances in Epilepsy. Churchill Livingstone, Edinburgh, pp. 21-44.
45. Muller D., Joly M., Lynch G. Contribution of quisqualate and NMDA receptors to the induction and expression of LTP. Science. 242:1988;1694-1697.
46. Mutani R., Cantello R., Gianelli M., Betticcu D. Rational basis for the development of new antiepileptic drugs. Epilepsy Res. 19:1991;23-28.
47. Namba T., Morimoto K., Sato K., Yamada N., Kuroda S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638:1994;36-44.
48. Oxley, J., 1986. Tolerance to the antiepileptic effect of clobazam in patients with severe epilepsy. In: Koella, W.P., Frey, H.H., Froscher, W., Meinardi, H. (Eds.), Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. Raven Press, New York, pp. 119-125.
49. Patel S., De Sarro G.B., Meldrum B.S. Regulation of seizure threshold by excitatory amino acids in the striatum and entopeduncular nucleus of rats. Neuroscience. 23:1988;837-850.
50. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. TIPS. 14:1993;325-331.
51. Saitoh H., Osonoe K., Osonoe M., Mori N., Kumashiro H. An important role of non-NMDA receptors in the expression of kindled amygdaloid seizure in rats. Jpn. J. Psychiatry Neurol. 45:1991;386-387.
52. Sato M., Racine R.J., McIntyre D.C. Kindling: basic mechanisms and clinical validity. Electroencephalogr. Clin. Neurophysiol. 76:1990;459-472.
53. Schmidt, D., Löscher, W., Oxley, J., 1986a. Clinical development of benzodiazepines and other antiepileptic drugs for intractable epilepsy. In: Schmidt, D., Morselli, P.L. (Eds.), Intractable Epilepsy, Raven Press, New York, pp. 219-225.
54. Schmidt, D., Rohde, M., Wolf, P., Roeder-Vanner, U., 1986b. Tolerance to the antiepileptic effect of clobazam. In: Koella, W.P., Frey, H.H., Froscher, W., Meinardi, H. (Eds.), Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. Raven Press, New York pp. 109-115.
55. Smith S., Chapman A.G. Acute and chronic anticonvulsant effects of D(-)CPPene in genetically epilepsy-prone rats. Epilepsy Res. 15:1993;193-199.
56. Smith S.E., Durmuller N., Meldrum B.S. The non-N-methyl-D-aspartate antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:1991;179-183.
57. Tarnawa I., Farkas S., Berzsenyi P., Pataki A., Andrasi F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 167:1989;193-199.
58. Turski L., Jacobsen P., Honorè T., Stephens D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther. 260:1992;742-747.
59. Velisek L., Kubova H., Mares P., Vachova D. Kainate/AMPA receptor antagonists are anticonvulsant against the tonic hindlimb component of pentylenetetrazol-induced seizures in developing rats. Pharmacol. Biochem. Behav. 51:1995;153-158.
60. Yamaguchi S., Donevan S.D., Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:1993;179-184.
61. Yanagita T., Takahashi S. Development of tolerance to and physical dependence on barbiturates in rhesus monkeys. J. Pharmacol. Exp. Ther. 172:1970;163-169.